For instance, a series of 467 cases found EGFR exon 19 deletion, along with EGFR L858R point mutations, in only 1% of cases, whereas ALK fusions were identified in 1.7% of patients, all being classified as NSCLC-like subtype. Here, EGFR is linked to non-small cell lung carcinoma.